Gastroenterology 1996; 111: 871–885. 26 Sasaki M, Joh T. Oxidative stress and ischemia-reperfusion injury in gastro- intestinal tract and antioxidant, protective agents. J Clin Biochem Nutr 2007; 40: 1–12. 27 Kokura S, Wolf RE, Yoshikawa T, Granger DN, Aw TY. Molecular mecha- nisms of neutrophil-endothelial cell adhesion induced by redox imbalance. Circ Res 1999; 84: 516–524. 28 Yoshida N, Yamaguchi T, Nakagawa S, Nakamura Y, Naito Y, Yoshikawa T. Role of P-selectin and intercellular adhesion molecule-1 in TNB-induced colitis in rats. Digestion 2001; 63: 81–86. 29 Nishimura T, Andoh A, Hashimoto T, Kobori A, Tsujikawa T, Fujiyama Y. Cellobiose prevents the development of dextran sulfate sodium (DSS)- induced experimental colitis. J Clin Biochem Nutr 2010; 46: 105–110. 30 Berlin C, Berg EL, Briskin MJ, and et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993; 74: 185–195. 31 Nakamura S, Ohtani H, Watanabe Y, and et al. In situ expression of the cell adhesion molecules in inflammatory bowel disease. Evidence of immunologic activation of vascular endothelial cells. Lab Invest 1993; 69: 77–85. 32 Schürmann GM, Bishop AE, Facer P, and et al. Increased expression of cell adhesion molecule P-selectin in active inflammatory bowel disease. Gut 1995; 36: 411–418. 33 Briskin MJ, McEvoy LM, Butcher EC. MAdCAM-1 has homology to immunoglobulin and mucin-like adhesion receptors and to IgA1. Nature 1993; 363: 461–464. 34 Holzmann B, Weissman IL. Peyer’s patch-specific lymphocyte homing receptors consist of a VLA-4-like alpha chain associated with either of two integrin beta chains, one of which is novel. EMBO J 1989; 8: 1735–1741. 35 Neuhaus H, Hu MC, Hemler ME, Takada Y, Holzmann B, Weissman IL. Cloning and expression of cDNAs for the alpha subunit of the murine lymphocyte-Peyer’s patch adhesion molecule. J Cell Biol 1991; 115: 1149– 1158. 36 Issekutz TB. Inhibition of in vivo lymphocyte migration to inflammation and homing to lymphoid tissues by the TA-2 monoclonal antibody. A likely role for VLA-4 in vivo. J Immunol 1991; 147: 4178–4184. 37 Yuan QA, Jiang WM, Krissansen GW, Watson JD. Cloning and sequence analysis of a novel beta 2-related integrin transcript from T lymphocytes: homology of integrin cysteine-rich repeats to domain III of laminin B chains. Int Immunol 1990; 2: 1097–1108. 38 Hu MC, Crowe DT, Weissman IL, Holzmann B. Cloning and expression of mouse integrin beta p(beta 7): a functional role in Peyer’s patch-specific lymphocyte homing. Proc Natl Acad Sci USA 1992; 89: 8254–8258. 39 Erle DJ, Briskin MJ, Butcher EC, Garcia-Pardo A, Lazarovits AI, Tidswell M. Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. J Immunol 1994; 153: 517–528. 40 Viney JL, Jones S, Chiu HH, and et al. Mucosal addressin cell adhesion molecule-1: a structural and functional analysis demarcates the integrin binding motif. J Immunol 1996; 157: 2488–2497. 41 Briskin M, Winsor-Hines D, Shyjan A, and et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997; 151: 97–110. 42 Souza HS, Elia CC, Spencer J, MacDonald TT. Expression of lymphocyte- endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut 1999; 45: 856–863. 43 Takeuchi M, Baichwal VR. Induction of the gene encoding mucosal vascular addressin cell adhesion molecule 1 by tumor necrosis factor alpha is mediated by NF-kappa B proteins. Proc Natl Acad Sci USA 1995; 92: 3561–3565. 44 Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 1995; 9: 899–909. 45 Oshima T, Pavlick KP, Laroux FS, and et al. Regulation and distribution of MAdCAM-1 in endothelial cells in vitro. Am J Physiol Cell Physiol 2001; 281: C1096–C1105. 46 Ando T, Jordan P, Wang Y, and et al. MAdCAM-1 expression and regulation in murine colonic endothelial cells in vitro. Inflamm Bowel Dis 2005; 11: 258–264. 47 Sasaki M, Elrod JW, Jordan P, and et al. CYP450 dietary inhibitors attenuate TNF-alpha-stimulated endothelial molecule expression and leukocyte adhe- 116 sion. Am J Physiol Cell Physiol 2004; 286: C931–C939. 48 Mizushima T, Sasaki M, Ando T, and et al. Blockage of angiotensin II type 1 receptor regulates TNF-alpha-induced MAdCAM-1 expression via inhibition of NF-kappaB translocation to the nucleus and ameliorates colitis. Am J Physiol Gastrointest Liver Physiol 2010; 298: G255–G266. 49 Katada K, Yoshida N, Suzuki T, and et al. Dextran sulfate sodium-induced acute colonic inflammation in angiotensin II type 1a receptor deficient mice. Inflamm Res 2008; 57: 84–91. 50 Sasaki M, Jordan P, Welbourne T, and et al. Troglitazone, a PPAR-gamma activator prevents endothelial cell adhesion molecule expression and lympho- cyte adhesion mediated by TNF-alpha. BMC Physiol 2005; 5: 3. 51 Hanauer SB, Feagan BG, Lichtenstein GR, and et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–1549. 52 Sands BE, Anderson FH, Bernstein CN, and et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350: 876–885. 53 Rutgeerts P, Sandborn WJ, Feagan BG, and et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462–2476. 54 Hanauer SB, Sandborn WJ, Rutgeerts P, and et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323–333. 55 Sandborn WJ, Hanauer SB, Rutgeerts P, and et al. Adalimumab for mainte- nance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 2007; 56: 1232–1239. 56 Sandborn WJ, Feagan BG, Stoinov S, and et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007; 357: 228–238. 57 Marzo-Ortega H, McGonagle D, O’Connor P, Emery P. Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis. Ann Rheum Dis 2003; 62: 74–76. 58 Hutas G. Golimumab, a fully human monoclonal antibody against TNFalpha. Curr Opin Mol Ther 2008; 10: 393–406. 59 Reinisch W, Hommes DW, Van Assche G. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn’s disease. Gut 2006; 55: 1138–1144. 60 Ito H, Takazoe M, Fukuda Y, and et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology 2004; 126: 989–996. 61 Sandborn WJ, Feagan BG, Fedorak RN, and et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology 2008; 135: 1130– 1141. 62 Krieglstein CF, Cerwinka WH, Sprague AG, and et al. Collagen-binding integrin alpha1beta1 regulates intestinal inflammation in experimental colitis. J Clin Invest 2002; 110: 1773–1782. 63 Takazoe M, Watanabe M, Kawaguchi T, and et al. Oral alpha-4 integrin Inhibitor (AJM300) in patients with active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009; 136 Suppl 1: 1240. 64 Sandborn WJ, Colombel JF, Enns R, and et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 2005; 353: 1912– 1925. 65 Feagan BG, Greenberg GR, Wild G, and et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352: 2499–2507. 66 Feagan BG, Greenberg GR, Wild G, and et al. Treatment of active Crohn’s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008; 6: 1370–1377. 67 Rijcken EM, Laukoetter MG, Anthoni C, and et al. Immunoblockade of PSGL-1 attenuates established experimental murine colitis by reduction of leukocyte rolling. Am J Physiol Gastrointest Liver Physiol 2004; 287: G115– G124. 68 Taniguchi T, Tsukada H, Nakamura H, and et al. Effects of the anti-ICAM-1 monoclonal antibody on dextran sodium sulphate-induced colitis in rats. J Gastroenterol Hepatol 1998; 13: 945–949. 69 Soriano A, Salas A, Sans M, and et al. VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab Invest 2000; 80: 1541–1551. doi: 10.3164/jcbn.1041 ©2011 JCBN